Home › Compound Library › Ropinirole (Requip)

Ropinirole (Requip)

Dopaminergicprescriptionoral · inferred

Non-ergot dopamine D2/D3 receptor agonist; approved for Parkinson's disease and restless legs syndrome. PD: titrate from 0.25 mg TID up to 8 mg TID; RLS: 0.25-4 mg QHS. Plasma half-life ~6h. Oral bioavailability ~50%. Extensively metabolized by CYP1A2, interactions with ciprofloxacin (inhibitor) and smoking (inducer). Shares impulse-control and somnolence warnings with other dopamine agonists.

Projected serum levels — 1 mg, once daily

Ropinirole (Requip)
Ropinirole (Requip) modeled serum levels, 1 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.25 0.50 0.75 1 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 1 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 0.45 mg, trough ≈ 0.035 mg body load. Population-based estimate over 15 days for a 1 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Dopaminergic
Route modeled
Oral
Model confidence
inferred
Half-life
6 h
Common dose
1 mg
Suggested maximum
24 mg/day
Reference dose range
0.50–24 mg (single dose)
Suggested cadence
once daily
Validated against
1 mg oral — Cmax 0.002 mg/L at 1.5 h

Documented interactions

  • danger
    Apigenin + Ropinirole (Requip) CYP inhibition

    Apigenin reversible_inhibitor of CYP1A2 predicted to change Ropinirole (Requip) AUC by ~2.97x

  • danger
    Ciprofloxacin (Cipro) + Ropinirole (Requip) CYP inhibition

    Ciprofloxacin (Cipro) reversible_inhibitor of CYP1A2 predicted to change Ropinirole (Requip) AUC by ~2.97x

  • danger
    Ethinyl Estradiol + Ropinirole (Requip) CYP inhibition

    Ethinyl Estradiol reversible_inhibitor of CYP1A2 predicted to change Ropinirole (Requip) AUC by ~2.97x

  • danger
    Fluvoxamine (Luvox) + Ropinirole (Requip) CYP inhibition

    Fluvoxamine (Luvox) reversible_inhibitor of CYP1A2 predicted to change Ropinirole (Requip) AUC by ~2.97x

  • danger
    Kava (Kavalactones) + Ropinirole (Requip) CYP inhibition

    Kava (Kavalactones) reversible_inhibitor of CYP1A2 predicted to change Ropinirole (Requip) AUC by ~2.97x

  • danger
    Methylene Blue + Ropinirole (Requip) CYP inhibition

    Methylene Blue reversible_inhibitor of CYP1A2 predicted to change Ropinirole (Requip) AUC by ~2.97x

Serum checks 31 modeled interaction pairings for ropinirole (requip) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Clinical pharmacokinetics of ropinirole Kaye CM et al. · Clinical Pharmacokinetics, 2000 DOI

    Comprehensive PK review: oral F ~50%, t1/2 ~6h, CYP1A2 metabolism, and smoking/ciprofloxacin interactions.

  2. Ropinirole: a review of its use in the treatment of Parkinson's disease Pahwa R et al. · Drugs, 2007 DOI

    Therapeutic review summarizing PK, clinical efficacy in early and advanced PD, and safety including impulse-control and somnolence signals.

2 published studies referenced in the app, each with a plain-language summary.